Replies to post #143268 on Biotech Values

[DewDiligence]

Re: Cancer drug candidates as a sucker bet

…I feel that way about most, if not all, biotech stocks. The real winners have been few and far between. For every AMGN, BIIB, GILD, etc., there have been probably twenty that have come and gone.

The distinction for cancer drugs, specifically, is the overabundant supply of drug candidates in clinical trials (#msg-76256791, #msg-76258438). No other area of biotech faces such a strong arithmetic headwind.